FDA approves Phase II clinical study application for New Small Molecule JAK1 Inhibitor SHR0302
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
ulcerative colitis is an autoimmune disease, inflammatory lesions are limited to the mucous membrane of the large intestine and the lower mucous membrane, mainly ulcer erosionThe lesions may affect the entire colonrecently, theof ThePharmaceuticals of Ruishi (LimitedCompany("Ruishi"),) officially announced that the U.SFDA(approved the Company's declared application for phase II clinical study of the new small molecule JAK1 inhibitor SHR0302)about SHR0302
SHR0302 licensed by Ruishi investor Jiangsu Hengrui Pharmaceutical Co., Ltd("Hengrui"), Ruishi has global interests in addition to rheumatoid arthritis and external skin sciencethis FDA approved this product for clinical studies of ulcerative colitisChina's clinical research declaration was completed at the end of August, and the European clinical research declaration is in progressRuishi Bio
pharmaceutical co., Ltd., founded in January 2018 and headquartered in Shanghai, China, with branches in Beijing and Boston, USA, is an innovative research and development-driven global bio
pharmaceutical(the company, based on the development of clinically urgently needednew drug(materials to meet the needs of patients)at present, Ruishi focuses on the innovation of autoimmune diseasesdrug(global development, on the one hand, with the domestic leading pharmaceuticalenterprises(Hengrui cooperation to introduce China's innovative drugs into the United States and Europe, to help China's innovation to the world;
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
